Initial Testing of the MDM2 Inhibitor RG7112 by the Pediatric Preclinical Testing Program

Pediatric Blood and Cancer - United States
doi 10.1002/pbc.24235
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Initial Testing (Stage 1) of Vorinostat (SAHA) by the Pediatric Preclinical Testing Program

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2009English

Initial Testing (Stage 1) of the Polyamine Analog PG11047 by the Pediatric Preclinical Testing Program

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2011English

Initial Testing of a Monoclonal Antibody (IMC-A12) Against IGF-1R by the Pediatric Preclinical Testing Program

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2010English

Initial Testing of Aplidin by the Pediatric Pre-Clinical Testing Program

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2009English

Combination Testing of Cediranib (AZD2171) Against Childhood Cancer Models by the Pediatric Preclinical Testing Program

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2011English

Initial Diagnostic Testing in the Evaluation of Pulmonary Hypertension

Advances in Pulmonary Hypertension
2005English

A Program Testing Assistant

Communications of the ACM
Computer Science
1982English

A Study Protocol Testing the Implementation, Efficacy, and Cost Effectiveness of the ezParent Program in Pediatric Primary Care

Contemporary Clinical Trials
MedicinePharmacology
2016English

Cellular Quiescence Caused by the Mdm2 Inhibitor Nutlin-3a

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy